Role Of Cellular Immunotherapies In Addressing Rising Prevalence Is Supporting Development Across The Cellular Immunotherapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Cellular Immunotherapy Market Compare Between 2026 And 2030?

The cellular immunotherapy market has experienced rapid growth in its size in recent years. It is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been attributed to the achievements of early CAR-T therapies, the existence of unmet oncology needs, increased research funding, regulatory approvals, and collaborations between academic institutions and industry.

The cellular immunotherapy market is set for significant expansion over the next few years. It is forecasted to achieve a valuation of $12.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.7%. This anticipated growth can be attributed to several factors including its expansion into solid tumors, continued innovation in nk cell therapy, the adoption of scalable manufacturing technologies, supportive regulatory frameworks, and increased oncology investment. Key trends expected during this period involve the rapid growth of car-t cell therapies, the broader application of allogeneic cell therapies, a rising use in hematologic malignancies, advancements in t cell engineering, and heightened clinical trial activity.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Are The Main Drivers Accelerating The Growth Of The Cellular Immunotherapy Market?

The increasing incidence of cancer is anticipated to fuel the expansion of the cellular immunotherapy market moving forward. Cancer refers to a collection of diseases marked by the uncontrolled multiplication and spread of abnormal cells throughout the body. The growing prevalence of cancer is largely a result of an aging population, lifestyle choices, and enhanced screening and diagnostic capabilities. Environmental exposures and genetic predispositions also play crucial roles in elevating incidence rates. Cellular immunotherapy boosts the immune system’s response against cancer by precisely targeting tumor cells, leading to improved survival rates. This technique, when combined with other therapies, could contribute to a reduction in cancer incidence and recurrence. For instance, in March 2024, according to MAC Clinical Research, a UK-based cancer research organization, the estimated number of individuals living with cancer in the United Kingdom is projected to rise from approximately 3 million at present to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the escalating prevalence of cancer is a key driver for the growth of the cellular immunotherapy market.

How Is Segment Classification Applied In The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

What Trends Are Impacting The Cellular Immunotherapy Market?

Leading entities within the cellular immunotherapy sector are concentrating on advancing technologies, notably immunotherapy itself, aiming to improve treatment effectiveness and broaden its utility. Key areas of their attention encompass personalized medical approaches, combined therapeutic strategies, and manufacturing processes that can be scaled, all designed to achieve superior patient results. Immunotherapy functions as a therapeutic method leveraging the body’s own immune system to combat illnesses, particularly cancer; this involves either stimulating immune responses or administering specific treatments to amplify immune action against particular cells. As an illustration, in December 2023, Max Healthcare Institute Limited operates as an India-based healthcare service provider company. CAR-T cell therapy represents a groundbreaking cancer treatment, employing genetically modified T cells to precisely identify and eliminate cancer cells, thereby providing a customized strategy. This therapy delivers lasting remission rates, especially for blood cancers that are resistant to other treatments, concurrently reducing harm to healthy body tissues.

Which Industry Players Are Present In The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Cellular Immunotherapy Market Report:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Has The Strongest Presence In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cellular Immunotherapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company

Cellulars Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Allergy Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795